Harness Therapeutics Ltd
Founded 2023 · 34 employees on LinkedIn · 4 known investors
Harness Therapeutics develops disease-modifying precision therapies for hard-to-treat neurodegenerative diseases through controlled modulation of CNS targets. Its pipeline targets conditions including Huntington's disease, Parkinson's disease, Alzheimer's disease, and ALS, using expertise in RNA biology and targeted protein modulation.
Founders & leadership
JT
Jan ThirkettleCEO Director
Investors · 4
Competitors · 2
by search overlapBioworld4 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Abcam3 shared keywordsSupplier of protein research tools to life scientists. Publicly listed on the LSE following an IPO.
Companies competing with Harness Therapeutics Ltd for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does Harness Therapeutics Ltd do?
- Harness Therapeutics develops disease-modifying precision therapies for hard-to-treat neurodegenerative diseases through controlled modulation of CNS targets. Its pipeline targets conditions including Huntington's disease, Parkinson's disease, Alzheimer's disease, and ALS, using expertise in RNA biology and targeted protein modulation.
- Who are Harness Therapeutics Ltd's investors?
- Harness Therapeutics Ltd's investors include Epidarex Capital, Ono Venture Investment, Inc., Dementia Discovery Fund, SV Health Investors.